Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: • Momentum fade • Breakout intact • Support holding Support Level: $18.00 to $17.80 Resistance Level: $19.90 to $20.75 RLAY is modestly higher over the last month, but after a breakout to $20.75 it has lost momentum and is now pulling back toward $18 support while facing resistance near $19.90 to $20.75.
Sentiment & News
Key News Insights: • Recurring contracts • Revenue acceleration • Insider profit-taking Relay Therapeutics is showing stronger commercial momentum with 46% revenue growth and its first recurring platform contracts, though a large insider sale after a major stock run-up adds caution.
AI Summary
RLAY has evolved from a purely speculative clinical-stage name into a more credible oncology platform story thanks to stronger data, Breakthrough Therapy validation, and early recurring revenue, but the stock still depends on executing upcoming trials/regulatory steps before dilution and cash needs force another reset.
Description
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental methods to improve small-molecule discovery, initially concentrating on targeted oncology and genetic disease indications. Its clinical programs include an FGFR2 inhibitor (RLY-4008) in first-in-human testing, a mutant PI3Ka inhibitor program (RLY-2608), and an SHP2 inhibitor (RLY-1971) in Phase 1, and the company maintains research collaborations with D. E. Shaw Research for protein-motion modeling and with Genentech for development and commercialization of RLY-1971. Founded in 2015, Relay Therapeutics is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | RLAY | Relay Therapeutics, Inc. | Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events. | Closed | +12.2% |